The WHO and those in charge of public health, the virologists and the pharmaceutical laboratories…. created a whole system around the imminence of a pandemic. There is a lot of money at stake, as well as networks of influence, careers and whole institutions! And the minute one of the flu viruses mutates we’d see the whole machine roll into action.
History tells us that the Spanish Flu in 1918 killed between 50-100 million people. It was considered as the most horrifying disease by medical and pharmaceutical sources. It is a wartime myth still being perpetuated to coverup the experimental military vaccines which killed millions during the Spanish Flu.
Following the Portuguese, German and Dutch rulings, now the Austrian court has ruled that PCR tests are not suitable for COVID-19 diagnosis and that lockdowns has no legal or scientific basis.
The Vienna Administrative Court granted a complaint by the FPÖ against the prohibition of its meeting registered for January 31 in Vienna.
“The prohibition was wrong,” the court said says in the ruling (read judgement below).
Dear colleagues in the fight against the evil & unjust “Vaccine Passports System”, right now being considered by the European Parliament,
Please find our weekend counterblast, from the Doctors4CovidEthics group.
"A first-of-its-kind literature review on the adverse effects of face masks, titled "Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?," reveals there are clear, scientifically demonstrable adverse effects for mask wearers, both on psychological, social and physical levels.
Newly published in the International Journal of Environmental Research and Public Health, a team of German researchers acknowledge that theirs is the first comprehensive investigation into the adverse health effects that masks can cause -- a surprising fact considering that many countries around the world introduced universal mask wearing in public spaces for containing SARS-CoV-2 in 2020 as a mandatory health policy without investigating nor communicating to their citizens the true risks of masks, hence violating informed consent.
According to the German research team, their work is designed to "provide a first, rapid, scientific presentation of the risks of general mandatory mask use by focusing on the possible adverse medical effects of masks, especially in certain diagnostic, patient and user groups."
There should be an open debate about the safety of wireless radiofrequency radiation. The Telecom industry has ignored the evidence about health effects of exposure to RFR since the introduction of radio and radar in the early 1900’s. And yet the evidence of direct biological effects at low power levels in fact runs into 1000’s of studies.
A pretty astounding announcement came from the UK this April 20th, with the prime minister seeming to have landed from another planet and having absolutely no clue of what he is talking about.
For sure, his advisers, mostly coming from big pharma, know extremely well that effective antivirals for COVID-19 already exist. In the past months, there has been a substantial lobby effort in the UK in favour of the Ivermectin, through the “BIRD” initiative.
In a shocking new report on the COVID-19 vaccines, it has been discovered that the Pfizer coronavirus vaccine has long term health effects not previously disclosed, including “ALS, Alzheimer’s, and other neurological degenerative diseases.”
This letter is in support of the petition for the suspension of vaccination against covid-19 which was presented to you by MM. Yativ and Seligmann.
I am Luc Montagnier, doctor of medicine, professor emeritus at the Institut Pasteur in Paris, director of research emeritus at CNRS, Nobel Prize in physiology or medicine for the discovery of the AIDS virus.
Prion diseases are fatal neurodegenerative conditions with highly accurate CSF and imaging diagnostic tests, but major unmet needs for blood biomarkers. Using ultrasensitive immuno-assays, we measured tau and neurofilament light chain (NfL) protein concentrations in 709 plasma samples taken from 377 individuals with prion disease during a 12 year prospective clinical study, alongside healthy and neurological control groups. This provides an unprecedented opportunity to evaluate their potential as biomarkers. Plasma tau and NfL were increased across all prion disease types. For distinguishing sCJD from control groups including clinically-relevant "CJD mimics", both show considerable diagnostic value. In sCJD, NfL was substantially elevated in every sample tested, including during early disease with minimal functional impairment and in all follow-up samples. Plasma tau was independently associated with rate of clinical progression in sCJD, while plasma NfL showed independent association with severity of functional impairment. In asymptomatic PRNP mutation carriers, plasma NfL was higher on average in samples taken within 2 years of symptom onset than in samples taken earlier. We present biomarker trajectories for nine mutation carriers healthy at enrolment who developed symptoms during follow-up. NfL started to rise as early as 2 years before onset in those with mutations typically associated with more slowly progressive clinical disease. This shows potential for plasma NfL as a "proximity marker", but further work is needed to establish predictive value on an individual basis, and how this varies across different PRNP mutations. We conclude that plasma tau and NfL have potential to fill key unmet needs for biomarkers in prion disease: as a secondary outcome for clinical trials (NfL and tau); for predicting onset in at-risk individuals (NfL); and as an accessible test for earlier identification of patients that may have CJD and require more definitive tests (NfL). Further studies should evaluate their performance directly in these specific roles.
Objective Drug-induced hemolytic anemia can occur in patients with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. The practice of G6PD-deficiency screening in the rheumatology field has been inconsistent. This study aimed to determine the utility of screening prior to the initiation of hydroxychloroquine and/or sulfasalazine in rheumatology patients in the ambulatory clinics at Stony Brook University Hospital, New York. Methods We conducted a retrospective chart review of cases of rheumatic diseases that were screened for G6PD deficiency at Stony Brook University Hospital ambulatory clinics. Demographic details and relevant clinical and laboratory data of the patients were collected. The data from similar studies in the literature were searched for and reviewed. Results This study consisted of 228 patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren's syndrome. Among those patients, 94.7% received hydroxychloroquine, sulfasalazine, or dapsone; 41% (89/228) of patients were screened for G6PD deficiency, and the majority of them were on treatment with hydroxychloroquine. Of those patients, 7.9% (five Caucasians and two African Americans) were found to have G6PD deficiency, and two of the G6PD-deficient patients received hydroxychloroquine. There was no incidence of hemolytic anemia documented in any of the seven patients with G6PD deficiency. We reviewed the literature and found three similar studies of patients receiving hydroxychloroquine with no reported hemolytic anemia from different medical centers in the US, and the frequency of G6PD deficiency reported in these studies was 1.4%, 4.0%, and 4.2%, respectively. Conclusions Our study suggests that the frequency of G6PD deficiency in our rheumatic population is similar to that of the general population, and the risk of hemolytic anemia in G6PD deficiency associated with hydroxychloroquine is extremely rare. Hence, G6PD screening may not be recommended prior to starting treatment with hydroxychloroquine.
Background: Glucose-6-phosphate dehydrogenase deficiency (G6PD) is linked to hemolytic anemia with certain medications and is the most common enzyme deficiency worldwide. Although the American College of Rheumatology does not recommend routine testing for G6PD prior to initiation of hydroxychloroquine (HCQ), the package insert for HCQ does recommend careful use in patients with G6PD deficiency.
Methods: We identified eligible subjects seen at our tertiary care, urban medical center between 1997 and 2018. Case records were analyzed for G6PD deficiency, HCQ use, length of exposure to HCQ, demographic characteristics, and laboratory evidence of hemolysis.
Results: We found 5264 patients who were prescribed HCQ, of which 49.5% (2605 patients) were screened for G6PD deficiency. Of the screened patients, 36 were found to be G6PD-deficient. Of the G6PD-deficient patients, 18 were exposed to HCQ. No evidence of hemolysis was found in these exposed patients.
Conclusions: Despite more than 500 months of cumulative exposure time to HCQ, there were no cases of hemolysis. These findings are in line with recently published data and suggest that this interaction is not associated with clinically significant hemolysis in our population of mainly African American and Hispanic patients. Limitations to our study are potential bias due to case review design and lack of prior assessment of episodes of hemolysis before HCQ exposure. A high proportion of our patients were Hispanic, suggesting no increase of adverse events in this subgroup. A larger longitudinal trial would be needed to definitively answer the question of the safety of HCQ in G6PD-deficient patients
The coronavirus disease 2019 (COVID-19) is until today a global health emergency. In an immense efort, efective drugs against COVID-19 are searched and intensive researches on possible repurposing of antiviral agents are performed. Since chloroquine (CQ) and hydroxychloroquine (HCQ) have shown in vitro anti- COVID-19 activities, the potential efect of CQ/ HCQ to treat and/or prevent COVID-19 infection has caused global attention.
New variants are of no concern. There is no need to cancel summer holidays. Millions vaccinated, coupled with immunity from millions of prior infections means we can surf on the crest of the third wave, rather than being remotely concerned about it. In fact, the UK should open now. And vaccine passports, certificates, or whatever name they are being given, will do nothing to improve the health of the population – all headlines we have read and heard over the past week or so.
Fear of symptom-free transmission was a major driver of the highly restrictive mitigation measures imposed over the past year.
ard data on the true prevalence of asymptomatic COVID-19 spread remains elusive, with scientists struggling to quantify just how often carriers of the SARS-Cov-2 virus transmit it without outward signs of illness.